Ongoing trade policies continue to shape the biopharmaceutical landscape, with the latest tariffs on key imports posing potential disruptions to clinical trials and drug development processes.
In a recent Clinical Trials Arena podcast, Anshul Mangal, President of Project Farma, shared his insights on how these tariffs could reshape the industry. Joined by Doug Drysdale, CEO of Cybin, the pair discussed critical industry implications, including:
- Rising costs in drug development
- Supply chain vulnerabilities
- Strategic industry response
- Industry implications
With expert perspectives on manufacturing resilience and policy adaptation, this podcast highlights important considerations for industry stakeholders navigating the evolving landscape of biopharmaceutical development under shifting trade dynamics.
Interested in the full discussion? Tune in to the Clinical Trials Arena Podcast: How Trump’s tariffs will impact clinical trials. Click here to listen now!
